Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mapatumumab with Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT00315757Phase 2Completed
- Sponsor
- Human Genome Sciences
- Start
- May 2006
- Primary completion
- Oct 2010
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of mapatumumab in multiple myeloma (MM) (3 arms), sponsored by Human Genome Sciences. Primary endpoint: Disease Response. Started May 2006; status: completed.
02
Drugs
mapatumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00315757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00315757.